Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Restoration of Effective Erythropoiesis and Iron Homeostasis Following Exagamglogene Autotemcel Treatment in Patients with Transfusion-Dependent β-Thalassemia

  • By

  • Sujit Sheth

  • Selim Corbacioglu

  • Josu de la Fuente

  • Mattia Algeri

  • Joachim Rupprecht

  • Kevin H. M. Kuo

  • Ami J. Shah

  • Peter Lang

  • Hayley Merkeley

  • Ben Carpenter

  • Markus Y. Mapara

  • Robert I. Liem

  • Stephan Grupp

  • Yogi Chopra

  • Amanda M. Li

  • Janet L. Kwiatkowski

  • Melanie Kirby-Allen

  • Maria Domenica Cappellini

  • Antonis Kattamis

  • Sakellarios Zairis

  • Tina Liu

  • William Hobbs

  • Haydar Frangoul

  • Franco Locatelli

  • Roland Meisel

  • June 7, 2026

Share

Clinical Scorecard: Restoration of Effective Erythropoiesis and Iron Homeostasis Following Exagamglogene Autotemcel Treatment in Patients with Transfusion-Dependent β-Thalassemia

At a Glance

CategoryDetail
ConditionTransfusion-Dependent β-Thalassemia
Key MechanismsIneffective erythropoiesis and iron overload due to mutations in the β-globin gene and repeated RBC transfusions.
Target PopulationPatients aged 12–35 years with confirmed diagnosis of transfusion-dependent thalassemia.
Care SettingClinical trials evaluating gene therapy and iron management.

Key Highlights

  • Exagamglogene autotemcel (exa-cel) led to transfusion independence in 91.4% of participants.
  • Mean total hemoglobin reached 13.1 g/dL and mean HbF was 11.9 g/dL post-treatment.
  • Iron overload is a significant complication due to ineffective erythropoiesis and repeated RBC transfusions.
  • Iron removal therapy is critical for managing iron overload in TDT patients.
  • Long-term follow-up studies assess safety and iron overload management.

Guideline-Based Recommendations

Diagnosis

  • Confirm diagnosis of transfusion-dependent thalassemia through genetic testing.

Management

  • Consider exa-cel therapy for eligible patients to achieve transfusion independence.

Monitoring & Follow-up

  • Regularly assess liver iron concentration and serum ferritin levels.

Risks

  • Monitor for complications related to iron overload, including cardiac and hepatic issues.

Patient & Prescribing Data

Patients with transfusion-dependent thalassemia aged 12–35 years.

Iron chelation therapy should be restarted based on specific hemoglobin and iron level criteria post-exa-cel infusion.

Clinical Best Practices

  • Implement iron removal therapy in all patients with transfusion-dependent thalassemia.
  • Monitor erythropoiesis and iron homeostasis markers post-treatment.

Related Resources & Content

Original Source(s)

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia

  • by Sujit Sheth, Selim Corbacioglu, Josu de la Fuente, Mattia Algeri, Joachim Rupprecht, Kevin H. M. Kuo, Ami J. Shah, Peter Lang, Hayley Merkeley, Ben Carpenter, Markus Y. Mapara, Robert I. Liem, Stephan Grupp, Yogi Chopra, Amanda M. Li, Janet L. Kwiatkowski, Melanie Kirby-Allen, Maria Domenica Cappellini, Antonis Kattamis, Sakellarios Zairis, Tina Liu, William Hobbs, Haydar Frangoul, Franco Locatelli, Roland Meisel

  • June 7, 2026

Related Content

Case Study: Two Instances of Idiopathic Plasmacytic Lymphadenopathy, a Subtype of Idiopathic Multicentric Castleman Disease, Accompanied by Xanthelasma Palpebrum from a Canadian Institution

Precision medicine in myelofibrosis: from molecular profiling to personalized therapy

Case Report: Atypical hepatobiliary manifestations associated with erythrocyte membrane instability in glucose transporter type 1 deficiency syndrome